Eli Lilly and Company (NYSE:LLY) Shares Acquired by Jag Capital Management LLC

Jag Capital Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 58.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,344 shares of the company's stock after acquiring an additional 8,971 shares during the period. Eli Lilly and Company comprises about 2.7% of Jag Capital Management LLC's holdings, making the stock its 12th largest holding. Jag Capital Management LLC's holdings in Eli Lilly and Company were worth $20,106,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $48,000. Highline Wealth Partners LLC raised its stake in Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after buying an additional 24 shares during the last quarter. Capital A Wealth Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $63,000. Finally, Bellwether Advisors LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $66,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $4.60 on Monday, hitting $780.05. The company's stock had a trading volume of 509,319 shares, compared to its average volume of 3,876,004. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $739.28 billion, a P/E ratio of 63.47, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a fifty day moving average price of $780.19 and a 200-day moving average price of $800.08.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period last year, the firm posted $2.58 EPS. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.